Press Releases

The pharmaceutical industry is a highly regulated and research-intensive sector dedicated to discovering, developing, manufacturing, and marketing drugs that improve human and animal health. It is characterized by long development timelines, significant financial investment, and strict regulatory oversight. Bringing a new drug to market typically requires 10 to 15 years of research and development and can cost more than one billion dollars. Because products are protected by patents that event

Ascentage Pharma Group International a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that its novel next-generation Bruton’s tyrosine kinase (BTK)-targeted protein degrader, APG-3288, has received investigational new drug (IND) application clearance from the China Center for Drug Evaluation (CDE) and is poised to enter a clin

Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that it has obtained exclusive commercialization rights in Japan to the ring‑type automated blood pressure monitor CART BP pro, from Sky Labs Inc. (Sky Labs) in South Korea. CART BP pro utilizes photoplethysmography (PPG) optical measurement technology to measure blood pressure without a cuff. This allows patients to monitor their blood pressure comfortably during daily activities, and monitoring is continued during sleep, enablin

Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat® KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit

Cycle Group Holdings Limited (“Cycle”) is delighted to announce it has completed the acquisition of NASDAQ-listed Applied Therapeutics, Inc. (NASDAQ: APLT; “Applied”), a clinical-stage biopharmaceutical company. Applied’s lead drug candidate, govorestat, is a novel central nervous system (CNS) penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including Classic Galactosemia, Charcot-Marie-Tooth Sorbitol Dehydrog

ZipBio, a biotechnology company pioneering AI-driven protein therapeutics, announced an exclusive license agreement with MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company. Under the agreement, MeiraGTx will receive exclusive rights to ZipBio's first-in-class therapies for Geographic Atrophy, targeting the complement pathway. The licensing deal leverages the strengths of both companies, combining MeiraGTx's leadership in v

SanegeneBio, a clinical-stage biotechnology company developing innovative RNAi therapeutics, today announced a global licensing agreement with Genentech, a member of the Roche Group, to advance one of its RNAi programs based on its proprietary RNAi platform. Under the agreement, SanegeneBio grants Genentech exclusive worldwide rights to develop and commercialize the program. SanegeneBio will be responsible for early development activities and Genentech will subsequently lead all future clinic

AstraZeneca today announced $15 billion investment in China through 2030 to expand medicines manufacturing and R&D. This investment will leverage the country’s scientific excellence, advanced manufacturing, and China-UK healthcare ecosystem collaborations to deliver cutting-edge treatments to patients across China and globally. Keir Starmer, UK Prime Minister, said: “Unlocking opportunities for British businesses across the globe and delivering for working people bac

Enveric Biosciences, Inc. a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that its subsidiary, Akos Biosciences, has licensed to TOTEC Pharma, Inc. (“TOTEC”) its US Trademark portfolio for RCANN™ and an RCANN™ design. TOTEC, an affiliate of Aries Science & Technology (“Aries”), is advancing the commercialization of patented cannabinoid crème te

IQVIA a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced a strategic long-term collaboration with Boehringer Ingelheim. Boehringer Ingelheim has selected IQVIA’s Data-as-a-Service (DaaS+) technology offering as the accelerator to power its global commercial data harmonization and transformation journey. This collaboration will enable Boehringer Ingelheim to sca